Barclays Maintains Overweight on TScan Therapeutics, Lowers Price Target to $3
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Peter Lawson maintains TScan Therapeutics (NASDAQ:TCRX) with a Overweight and lowers the price target from $14 to $3.
Barclays analyst Peter Lawson maintains TScan Therapeutics (NASDAQ:TCRX) with a Overweight and lowers the price target from $14 to $3.